A new report has suggested that a drug developed for tackling cancer could have positive effects for babies at risk of developing eye diseases.
Published in the New England Journal of Medicine, the research suggested that an injection of bevacizumab, also known as Avastin, could reduce the risk of retinal detachment in premature infants and reduce the need for contact lenses later in life.
According to the scientists, babies born prematurely "inevitably lose some peripheral field vision and often develop myopia [short-sightedness]", while "complications can also include cataracts and glaucoma".
The study revealed that, out of 300 children tested, the rate of recurrence of retinopathy of prematurity was just four per cent for those given the drug, compared to 22 per cent for those using other methods.
Recently, the Hamilton Glaucoma Center at the University of California said that a newly-developed contact lens with an embedded pressure sensor could help monitor and manage glaucoma in adults.
by Alexa Kaczka